Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2)
Top Cited Papers
Open Access
- 14 April 2017
- journal article
- research article
- Published by Elsevier BV in Journal of the American Academy of Dermatology
- Vol. 77 (2), 310-317.e1
- https://doi.org/10.1016/j.jaad.2017.01.052
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Evaluation of the Effect of Tofacitinib Exposure on Outcomes in Kidney Transplant PatientsAmerican Journal of Transplantation, 2015
- Longterm (52-week) Results of a Phase III Randomized, Controlled Trial of Apremilast in Patients with Psoriatic ArthritisThe Journal of Rheumatology, 2015
- Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunityCellular Signalling, 2014
- The Prevalence and Odds of Depressive Symptoms and Clinical Depression in Psoriasis Patients: A Systematic Review and Meta-AnalysisJournal of Investigative Dermatology, 2014
- Prevalence of Psoriasis Among Adults in the U.S.American Journal of Preventive Medicine, 2014
- Psoriasis prevalence among adults in the United StatesJournal of the American Academy of Dermatology, 2014
- Cystic Fibrosis Transmembrane Conductance Regulator Activation by Roflumilast Contributes to Therapeutic Benefit in Chronic BronchitisAmerican Journal of Respiratory Cell and Molecular Biology, 2014
- Global Epidemiology of Psoriasis: A Systematic Review of Incidence and PrevalenceJournal of Investigative Dermatology, 2013
- Patient Preferences for Psoriasis TreatmentsArchives of Dermatology, 2011
- The human area postrema and other nuclei related to the emetic reflex express cAMP phosphodiesterases 4B and 4DJournal of Chemical Neuroanatomy, 2010